Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 6
2005 3
2006 5
2007 1
2008 5
2009 5
2010 6
2011 8
2012 3
2013 3
2014 11
2015 10
2016 7
2017 4
2018 5
2019 6
2020 12
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Results by year
Filters applied: . Clear all
Page 1
Limitations of non-invasive tests for assessment of liver fibrosis.
Patel K, Sebastiani G. Patel K, et al. JHEP Rep. 2020 Jan 20;2(2):100067. doi: 10.1016/j.jhepr.2020.100067. eCollection 2020 Apr. JHEP Rep. 2020. PMID: 32118201 Free PMC article. Review.
The diagnostic assessment of liver injury is an important step in the management of patients with chronic liver disease (CLD). Although liver biopsy is the reference standard for the assessment of necroinflammation and fibrosis, the inherent limitations of an …
The diagnostic assessment of liver injury is an important step in the management of patients with chronic liver disease (CLD). …
Fibroscan.
Patel K, Wilder J. Patel K, et al. Clin Liver Dis (Hoboken). 2014 Dec 9;4(5):97-101. doi: 10.1002/cld.407. eCollection 2014 Nov. Clin Liver Dis (Hoboken). 2014. PMID: 30992931 Free PMC article. Review. No abstract available.
Hepatic Stellate Cells and Hepatocarcinogenesis.
Barry AE, Baldeosingh R, Lamm R, Patel K, Zhang K, Dominguez DA, Kirton KJ, Shah AP, Dang H. Barry AE, et al. Among authors: patel k. Front Cell Dev Biol. 2020 Aug 5;8:709. doi: 10.3389/fcell.2020.00709. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32850829 Free PMC article. Review.
Activated HSCs transform into myofibroblast-like cells to promote fibrosis in response to liver injury or chronic inflammation, leading to cirrhosis and HCC. ...Since activated HSCs are primary secretors of ECM proteins during liver injury and inflammation, they hel …
Activated HSCs transform into myofibroblast-like cells to promote fibrosis in response to liver injury or chronic inflammation, leadi …
Treatment of HCV infection by targeting microRNA.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Janssen HL, et al. Among authors: patel k. N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27. N Engl J Med. 2013. PMID: 23534542 Free article. Clinical Trial.
BACKGROUND: The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122). Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that …
BACKGROUND: The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and …
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Patel K, et al. Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205. Hepatology. 2020. PMID: 32115759 Clinical Trial.
MRI-PDFF, liver stiffness by MRE and transient elastography, and serum markers of fibrosis were measured at baseline and week 24. ...Serum gamma-glutamyltransferase, C4, and primary bile acids decreased significantly at week 24 in both cilofexor treatment groups, whereas s …
MRI-PDFF, liver stiffness by MRE and transient elastography, and serum markers of fibrosis were measured at baseline and week 24. ... …
Reply.
Galvin Z, Patel K, Bhat M. Galvin Z, et al. Among authors: patel k. Liver Transpl. 2019 Jun;25(6):969-970. doi: 10.1002/lt.25465. Epub 2019 Apr 29. Liver Transpl. 2019. PMID: 30947397 No abstract available.
Reply.
Choi HSJ, Brouwer WP, Hansen BE, Janssen HLA, Patel K. Choi HSJ, et al. Among authors: patel k. Hepatology. 2020 Feb;71(2):769. doi: 10.1002/hep.30980. Epub 2020 Jan 28. Hepatology. 2020. PMID: 31593309 No abstract available.
Reply.
Patel K, Chung C, Myers RP. Patel K, et al. Hepatology. 2020 Dec;72(6):2241-2242. doi: 10.1002/hep.31402. Epub 2020 Nov 20. Hepatology. 2020. PMID: 32490551 No abstract available.
NASH in HIV.
Cervo A, Shengir M, Patel K, Sebastiani G. Cervo A, et al. Among authors: patel k. Curr HIV/AIDS Rep. 2020 Dec;17(6):601-614. doi: 10.1007/s11904-020-00531-0. Curr HIV/AIDS Rep. 2020. PMID: 32984925 Review.
Nonalcoholic fatty liver disease (NAFLD) seems a frequent comorbidity in aging PWH nowadays. NAFLD results from a fat deposition into the liver parenchyma that may evolve to nonalcoholic steatohepatitis (NASH), a state of hepatocellular inflammation and injury in re …
Nonalcoholic fatty liver disease (NAFLD) seems a frequent comorbidity in aging PWH nowadays. NAFLD results from a fat deposition into …
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Foster GR, et al. Among authors: patel k. N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17. N Engl J Med. 2015. PMID: 26575258 Free article. Clinical Trial.
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page